Muscarinic receptor agonists and antagonists

Author： Zlotos D.P. Bender W. Holzgrabe U.

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.9, Iss.8, 1999-08, pp. : 1029-1053

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimer's Disease

Current Pharmaceutical Design, Vol. 11, Iss. 26, 2005-10 ,pp. : 3353-3361

Bentham Science Publishers

Access to resources Recommend Favorite

Muscarinic Receptor Antagonists

By Watson N. Eglen R.M.

Pulmonary Pharmacology & Therapeutics, Vol. 12, Iss. 2, 1999-04 ,pp. : 115-118

Academic Press

Access to resources Recommend Favorite

Muscarinic M1 receptor agonists and M2 receptor antagonists as therapeutic targets in Alzheimer’s disease

By Sheardown Malcolm J

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 6, 2002-06 ,pp. : 863-870

Informa Healthcare

Access to resources Recommend Favorite

Progesterone receptor agonists and antagonists

By Allan G. Macielag M.

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 7, 1999-07 ,pp. : 955-962

Informa Healthcare

Access to resources Recommend Favorite

Cannabinoid receptor agonists and antagonists

By Barth F.

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 3, 1998-03 ,pp. : 301-313

Informa Healthcare

Access to resources Recommend Favorite